Zoetis Inc. (ZTS) Stock Analysis
Temp Headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $114.45 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 2.8): -1.5; Earnings in 7 days (event risk).
Zoetis commercializes animal health medicines, vaccines, and diagnostics across eight species in two segments: U.S. ($5,097M, 54% of revenue) and International ($4,254M, 45%) for the year ended December 31, 2025. Revenue comes from product sales to veterinarians and livestock... Read more
Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $114.45 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 2.8): -1.5; Earnings in 7 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, high confidence.
Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductfive top-selling products42%10-K Item 1A: 'our five top-selling products ... contributed approximately 42% of our revenue in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $114.45 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 2.8): -1.5; Earnings in 7 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $109.58. Score 5.3/10, high confidence.
Take-profit target: $134.68 (+17.7% upside). Prior stop was $109.58. Stop-loss: $109.58.
Leverage penalty (D/E 2.8): -1.5; Earnings in 7 days (event risk); Weak growth.
Zoetis Inc. trades at a P/E of 18.9 (forward 15.0). TrendMatrix value score: 6.4/10. Verdict: Sell.
25 analysts cover ZTS with a consensus score of 3.8/5. Average price target: $150.
What does Zoetis Inc. do?Zoetis commercializes animal health medicines, vaccines, and diagnostics across eight species in two segments: U.S....
Zoetis commercializes animal health medicines, vaccines, and diagnostics across eight species in two segments: U.S. ($5,097M, 54% of revenue) and International ($4,254M, 45%) for the year ended December 31, 2025. Revenue comes from product sales to veterinarians and livestock producers; top five product lines contributed ~42% of 2025 revenue.